$720M in the FoB deal, according to the WSJ: Seems like big amount(even if upfront money is low), since Phase 3 trial just started ? Also, biosimilar not necessarily biosame (substitutable) ...doubt would be able to capture marketshare maybe the deal is based on achieving sales milestones